InterMune's CEO Discusses Q2 2012 Earnings - Earnings Call Transcript

InterMune Inc. (ITMN)

Q2 2012 Earnings Call

July 23, 2012 8:30 am ET

Executives

Daniel Welch – President, Chief Executive Officer

John Hodgman – Senior Vice President, Chief Financial Officer

Giacomo Di Nepi – Managing Director, Europe

Dr. Markus Leyck Dieken – Country Manager, Germany

Jim Goff – Vice President, Investor Relations

Analysts

Michael Yee – RBC Capital Markets

Brian Abrahams – Wells Fargo

Ritu Baral – Canaccord

Geoff Meacham – JP Morgan

Brian Skorney – Brean Murray

Matthew Harrison – UBS

Terence Flynn – Goldman Sachs

Liisa Bayko – JMP Securities

Howard Liang – Leerink Swann

Ravi Mehrotra – Credit Suisse

Katherine Xu – William Blair

Stephen Willey – Stifel Nicolaus

Presentation

Operator

Ladies and gentlemen, thank you for standing by and welcome to the InterMune Second Quarter 2012 Results conference call. During the presentation, all participants will be in a listen-only mode. Afterwards we will conduct a question and answer session. At that time, if you do have questions you may press the one followed by the four. If you require operator assistance at any time during the conference, you may press star, zero. As a reminder, this conference is being recorded Monday, July 23, 2012.

I would now like to turn the conference over to Jim Goff, Vice President, Investor Relations. You may begin, sir.

Jim Goff

Thank you, Operator. Good morning and welcome to the InterMune earnings conference call. This morning we issued a press release that provides details of the Company’s unaudited financial results for the second quarter and first six months ended June 30, 2012 as well as the completion of price discussions for Esbriet in Germany. The press release is available on our website at www.intermune.com.

During the course of this conference call, we will state our beliefs and make projections and other forward-looking statements regarding future events and the future financial performance of InterMune. We wish to caution you that such statements are predictions and expectations and actual events or results may differ materially. We refer you to the Company’s publicly filed SEC disclosure documents for a detailed description of the risk factors affecting our business, including those discussed in our Form 10-K filed with the SEC on February 29, 2012. These documents identify important factors that could cause our actual results to differ materially from our projections and other forward-looking statements. These risk factors include regulatory, revenue, intellectual property, clinical development, capital resources and other risks relating to our business.

If you liked this article you might like

Week in Review: Trump Rally Fizzles but Stocks End 2016 With Big Gains

Post-Trump Rally Stalls as Dow Jones Slips Further From 20,000 Mark

Stocks Slump Continues With All S&P 500 Sectors in Negative Territory

Hacking Case Shows Mounting Risk for M&A Law Firms, Corporate Clients

Stocks Turn Negative, Prolonging Dow's Trek Toward 20,000